Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 12, 2019. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £15.5433 per share.
- Transaction Volume: 16 shares per individual (comprising 8 partnership shares and 8 matching shares).
- Total Value per Individual: Approximately £248.69.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. It solely discloses routine acquisitions of shares under the Company's Share Reward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of compliance with insider trading reporting requirements.
Important Facts for Investors
- Transaction Type: All reported transactions were acquisitions of Ordinary Shares under the Company's Share Reward Plan, not open market purchases or sales.
- Participants: The filing lists 10 senior executives, including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and various Presidents and SVPs.
- Uniformity: Every listed executive executed an identical transaction on February 11, 2019, on the London Stock Exchange (XLON).
- Scale: The volume of shares acquired by each individual (16 shares) is negligible relative to the company's total share capital and does not indicate significant insider sentiment shifts.